RE:RE:RE:RE:RE:VideoPossibly this is the way it has to start. Theralase must demonstrate the safety and efficacy of it's treatment under circumstances where it is unlikely to do harm before it will be considered for a trial where it is used as a replacement for the current front line treatments.
The patients we are treating would probably have to have their bladders removed if it weren't for this experimental "Hail Mary pass" Theralase trial. But f we end up with nine or six patients who get to keep their bladders then maybe the Theralase treatment as a front line treatment might not be considered such a "hard sell" (as Dr. Kulkarni put it)
I'm wondering if the ph2b trial will be the same and if we will have to wait 2 more years before we will be considered for a front line treatment trial - or - if the treatment proves very efficacious, the process can be accelerated. There are also the ph1b trials for other indications coming up next year.
fredgoodwinson wrote: Precisely woundedknee - and the whole tone of Dr.Kulkarni`s answers were along the lines of 'Don`t even think of asking Health Canada to use TLD-1433 as a front line treatment as refusal only offends'.